Ruben Diaz Avalos

Ruben Diaz Avalos

Auto-generated profile, based on publicly available information

Ruben Diaz Avalos

Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2022 in Science Advances
Verified
Journal Article
Open access
HCHeather M. Callaway
Heather M. Callaway
DZDawid S Zyla
Dawid S Zyla
FLFlorence Larrous
Florence Larrous
GMGuilherme Dias de Melo
Guilherme Dias de Melo
KHKathryn M. Hastie
Kathryn M. Hastie
ESErica Ollmann Saphire
Erica Ollmann Saphire
Rabies infection is nearly 100% lethal if untreated and kills more than 50,000 people annually, many of them children. Existing rabies vaccines target the rabies virus glycoprotein (RABV-G) but generate short-lived immune responses, likely because the protein is heterogeneous under physiological conditions. Here, we report the 3.39 Å cryo–electron microscopy structure of trimeric, prefusion RABV-G complexed with RVA122, a potently neutralizing human antibody. RVA122 binds to a quaternary epitope at the top of RABV-G, bridging domains and stabilizing RABV-G protomers in a prefusion state. RABV-G trimerization involves side-to-side interactions between the central α helix and adjacent loops, rather than contacts between central helices, and interactions among the fusion loops at the glycoprotein base. These results provide a basis from which to develop improved rabies vaccines based on RABV-G stabilized in the prefusion conformation.

28 June 2024 in Science
Verified
Journal Article
Closed access
DZDawid S Zyla
Dawid S Zyla
RMRoberta Della Marca
Roberta Della Marca
GNGele Niemeyer
Gele Niemeyer
GZGillian Zipursky
Gillian Zipursky
KSKyle Stearns
Kyle Stearns
ESErica Ollmann Saphire
Erica Ollmann Saphire
Measles virus (MeV) presents a public health threat that is escalating as vaccine coverage in the general population declines and as populations of immunocompromised individuals, who cannot be vaccinated, increase. There are no approved therapeutics for MeV. Neutralizing antibodies targeting viral fusion are one potential therapeutic approach but have not yet been structurally characterized or advanced to clinical use. We present cryo–electron microscopy (cryo-EM) structures of prefusion F alone [2.1-angstrom (Å) resolution], F complexed with a fusion-inhibitory peptide (2.3-Å resolution), F complexed with the neutralizing and protective monoclonal antibody (mAb) 77 (2.6-Å resolution), and an additional structure of postfusion F (2.7-Å resolution). In vitro assays and examination of additional EM classes show that mAb 77 binds prefusion F, arrests F in an intermediate state, and prevents transition to the postfusion conformation. These structures shed light on antibody-mediated neutralization that involves arrest of fusion proteins in an intermediate state.

26 October 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
HLHaoyang Li
Haoyang Li
TBTierra Buck
Tierra Buck
MZMichelle Zandonatti
Michelle Zandonatti
JYJieyun Yin
Jieyun Yin
AMAlex Moon-Walker
Alex Moon-Walker
ESErica Ollmann Saphire
Erica Ollmann Saphire
Developing potent therapeutics and effective vaccines are the ultimate goals in controlling infectious diseases. Lassa virus (LASV), the causative pathogen of Lassa fever (LF), infects hundreds of thousands annually, but effective antivirals or vaccines against LASV infection are still lacking. Furthermore, neutralizing antibodies against LASV are rare. Here, we describe biochemical analyses and high-resolution cryo-electron microscopy structures of a therapeutic cocktail of three broadly protective antibodies that target the LASV glycoprotein complex (GPC), previously identified from survivors of multiple LASV infections. Structural and mechanistic analyses reveal compatible neutralizing epitopes and complementary neutralization mechanisms that offer high potency, broad range, and resistance to escape. These antibodies either circumvent or exploit specific glycans comprising the extensive glycan shield of GPC. Further, they require mammalian glycosylation, native GPC cleavage, and proper GPC trimerization. These findings guided engineering of a next-generation GPC antigen suitable for future neutralizing antibody and vaccine discovery. Together, these results explain protective mechanisms of rare, broad, and potent antibodies and identify a strategy for the rational design of therapeutic modalities against LF and related infectious diseases.

6 May 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
EOEduardo Olmedillas
Eduardo Olmedillas
CMColin J. Mann
Colin J. Mann
WPWeiwei Peng
Weiwei Peng
YWYing-Ting Wang
Ying-Ting Wang
RARuben Diaz Avalos
Ruben Diaz Avalos
ESErica Ollmann Saphire
Erica Ollmann Saphire
SUMMARY: The continued threat of SARS-CoV-2 to global health necessitates development of improved research tools and vaccines. We present an improved SARS-CoV-2 spike ectodomain, “VFLIP”, bearing five proline substitutions, a flexible cleavage site linker, and an inter-protomer disulfide bond. VFLIP displays significantly improved stability, high-yield production and retains its trimeric state without exogenous trimerization motifs. High-resolution cryo-EM and glycan profiling reveal that the VFLIP quaternary structure and glycosylation mimic the native spike on the viral surface. Further, VFLIP has enhanced affinity and binding kinetics relative to other stabilized spike proteins for antibodies in the Coronavirus Immunotherapeutic Consortium (CoVIC), and mice immunized with VFLIP exhibit potent neutralizing antibody responses against wild-type and B.1.351 live SARS-CoV-2. Taken together, VFLIP represents an improved tool for diagnostics, structural biology, antibody discovery, and vaccine design.

29 August 2025 in Science Advances
Verified
Journal Article
Open access
JSJeremy Shek
Jeremy Shek
CSChen Sun
Chen Sun
EWElise Marie Wilson
Elise Marie Wilson
FMFatemeh Moadab
Fatemeh Moadab
KHKathryn M. Hastie
Kathryn M. Hastie
ESErica Ollmann Saphire
Erica Ollmann Saphire
Human endogenous retroviruses (HERVs) are remnants of ancient infections that comprise ~8% of the human genome. The HERV-K envelope glycoprotein (Env) is aberrantly expressed in cancers, autoimmune disorders, and neurodegenerative diseases, and is targeted by patients’ own antibodies. However, a lack of structural information has limited molecular and immunological studies of the roles of HERVs in disease. Here, we present cryo–electron microscopy structures of stabilized HERV-K Env in the prefusion conformation, revealing a distinct fold and architecture compared to HIV and simian immunodeficiency virus. We also generated and characterized a panel of monoclonal antibodies with subunit and conformational specificity, serving as valuable research tools. These antibodies enabled structure determination of the postfusion conformation of HERV-K Env, including its unique “tether” helix, and antibody-bound prefusion Env. Together, these results provide a structural framework that opens the door to mechanistic studies of HERV-K Env and tools for its evaluation as a potential therapeutic target.

17 July 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
AMAlex Moon-Walker
Alex Moon-Walker
ZZZeli Zhang
Zeli Zhang
DZDawid S Zyla
Dawid S Zyla
TBTierra K. Buck
Tierra K. Buck
HLHaoyang Li
Haoyang Li
ESErica Ollmann Saphire
Erica Ollmann Saphire
Summary: The mammarenavirus Lymphocytic choriomeningitis virus (LCMV) is a globally distributed zoonotic pathogen that can be lethal in immunocompromised patients and cause severe birth defects if acquired during pregnancy. Despite the fundamental importance of LCMV for studying immunobiology, the structure of the trimeric surface glycoprotein, essential for entry, vaccine design and antibody neutralization, remains unknown. In this study, we present the cryoEM structure of the LCMV surface glycoprotein (GP) in its trimeric prefusion assembly both alone and in complex with a rationally engineered monoclonal neutralizing antibody termed 18.5C-M28 (M28). Additionally, we show that passive administration of M28 protects mice from LCMV clone 13 (LCMV cl13 ) challenge when administered as either a prophylactic or therapeutic. Our study illuminates not only the overall structural organization of LCMV GP and the mechanism for its inhibition by M28, but also presents a promising therapeutic candidate to prevent severe or fatal disease in individuals who are at risk of infection by a virus that poses a threat worldwide. Highlights: Rationally-engineered antibody M28 neutralizes lymphocytic choriomeningitis virus in vitro . First high-resolution cryoEM structure of the pre-fusion trimeric lymphocytic choriomeningitis virus glycoprotein alone and in complex with M28. M28 neutralizes by bridging adjacent glycoprotein protomers and locking it in the pre-fusion state. Prophylactic and therapeutic administration of M28 protects mice from chronic lymphocytic choriomeningitis virus infection.